Literature DB >> 25801560

In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.

Natália Barth1, Vanessa B Ribeiro2, Alexandre P Zavascki3.   

Abstract

We evaluated the in vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against six KPC-2-producing Enterobacteriaceae strains with high MICs for these antimicrobial agents. Polymyxin B with carbapenems, especially meropenem, were the most active combinations for Klebsiella pneumoniae and Enterobacter cloacae regardless of the polymyxin B concentration used in the time-kill assay. This combination was also synergistic against two Serratia marcescens strains that are intrinsically resistant to polymyxins. Polymyxin B and tigecycline also presented synergistic activity in most experiments.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801560      PMCID: PMC4432205          DOI: 10.1128/AAC.00365-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.

Authors:  Jonathan W Betts; Lynette M Phee; Michael Hornsey; Neil Woodford; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

Review 2.  Susceptibility testing of the polymyxins: where are we now?

Authors:  Romney M Humphries
Journal:  Pharmacotherapy       Date:  2014-10-20       Impact factor: 4.705

3.  Molecular characterization of Klebsiella pneumoniae carbapenemase-producing isolates in southern Brazil.

Authors:  Vanessa Bley Ribeiro; Leonardo Neves Andrade; Adriano Rostirolla Linhares; Juliana Barin; Ana Lúcia da Costa Darini; Alexandre P Zavascki; Afonso Luis Barth
Journal:  J Med Microbiol       Date:  2013-09-02       Impact factor: 2.472

Review 4.  Combination therapy for carbapenem-resistant Gram-negative bacteria.

Authors:  Alexandre P Zavascki; Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091

Review 5.  Tigecycline: an update.

Authors:  Gary E Stein; Timothy Babinchak
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-26       Impact factor: 2.803

Review 6.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

Review 7.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

Review 8.  Treating infections caused by carbapenemase-producing Enterobacteriaceae.

Authors:  L S Tzouvelekis; A Markogiannakis; E Piperaki; M Souli; G L Daikos
Journal:  Clin Microbiol Infect       Date:  2014-07-12       Impact factor: 8.067

9.  Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.

Authors:  Alexandre P Zavascki
Journal:  Expert Rev Anti Infect Ther       Date:  2014-03-25       Impact factor: 5.091

  9 in total
  7 in total

1.  In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Teo; Suranthran Sasikala; Winnie Lee; Yanjun Hong; Eric Chun Yong Chan; Thean Yen Tan; Thuan-Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.

Authors:  John K Diep; David M Jacobs; Rajnikant Sharma; Jenna Covelli; Dana R Bowers; Thomas A Russo; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

3.  Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  J Vis Exp       Date:  2019-04-18       Impact factor: 1.355

4.  In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.

Authors:  Dennis Huang; Brenda Yu; John K Diep; Rajnikant Sharma; Michael Dudley; Jussimara Monteiro; Keith S Kaye; Jason M Pogue; Cely Saad Abboud; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on In Vitro Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ippei Yoshida; Iichiro Takata; Kiyoko Fujita; Hajime Takashima; Hiroyuki Sugiyama
Journal:  Microbiol Spectr       Date:  2022-06-01

6.  The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.

Authors:  Yongxin Zhao; Chunjiang Li; Jisheng Zhang; Yanjun Fu; Kewang Hu; Shanshan Su; Yong Wang; Huiling Li; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2019-12

Review 7.  Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.

Authors:  Suneel Kumar Garg; Omender Singh; Deven Juneja; Niraj Tyagi; Amandeep Singh Khurana; Amit Qamra; Salman Motlekar; Hanmant Barkate
Journal:  Crit Care Res Pract       Date:  2017-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.